Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are both investigated for their effects on glucose metabolism and body composition. The critical distinction is that semaglutide is a single-target GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist.
Side-by-Side Comparison
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Category | GLP-1 receptor agonist (single agonist) | GIP/GLP-1 dual receptor agonist (twincretin) |
| Mechanism of Action | Mimics endogenous GLP-1; activates GLP-1 receptor to stimulate insulin secretion, suppress glucagon, slow gastric emptying | Activates both GIP and GLP-1 receptors simultaneously; enhances insulin sensitivity through dual incretin pathways |
| Molecular Weight | ~4,113 Da | ~4,810 Da |
| Primary Research Focus | Type 2 diabetes, obesity, cardiovascular risk reduction, NASH/MAFLD | Type 2 diabetes, obesity, cardiovascular outcomes, combined metabolic syndrome |
| Receptor Target | GLP-1 receptor (selective) | GIP receptor (primary) + GLP-1 receptor (secondary) |
| Half-Life | ~7 days (albumin binding via C-18 fatty diacid) | ~5 days (C-20 fatty diacid moiety enables albumin binding) |
| Key Research Citations | Wilding et al. (2021), STEP trials, NEJM; Marso et al. (2016), SUSTAIN-6, NEJM | Jastreboff et al. (2022), SURMOUNT-1, NEJM; Frias et al. (2021), SURPASS trials, NEJM |
Key Differences
- Semaglutide targets a single receptor (GLP-1R), while tirzepatide simultaneously activates two incretin receptors (GIP and GLP-1), representing a distinct pharmacological approach.
- Tirzepatide demonstrated greater body weight reduction in head-to-head clinical comparisons (SURPASS-2), though both compounds show significant efficacy.
- Semaglutide has a longer half-life (~7 days vs ~5 days), primarily due to differences in their fatty acid side chain modifications.
- Semaglutide has established cardiovascular outcome data from the SUSTAIN-6 and SELECT trials; tirzepatide cardiovascular outcome trials are ongoing.
Research Summary
The fundamental difference between semaglutide and tirzepatide lies in receptor pharmacology. Semaglutide is a selective GLP-1 receptor agonist with extensive clinical evidence across metabolic and cardiovascular endpoints. Tirzepatide introduces a dual agonist mechanism targeting both GIP and GLP-1 receptors, which may account for its enhanced metabolic effects observed in comparative studies. Both compounds have extended half-lives through albumin-binding fatty acid modifications, enabling once-weekly research protocols.
How does semaglutide compare to tirzepatide?
Semaglutide is a selective GLP-1 receptor agonist with a ~7-day half-life, while tirzepatide is a dual GIP/GLP-1 receptor agonist with a ~5-day half-life. The key distinction is that tirzepatide activates two incretin receptors simultaneously, which may account for the greater metabolic effects observed in head-to-head clinical trials such as SURPASS-2.
More Comparisons
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.